The decision to exercise the put option allows DRI to sell the asset back to the issuer at a pre-negotiated price. This move coincides with the broader takeover of KalVista by the Italian pharmaceutical giant Chiesi Group, a transaction that provided the necessary framework for the royalty payout. DRI officials confirmed that the funds are expected to arrive in corporate accounts no later than mid-August. By utilizing this financial mechanism, the firm eliminates its long-term exposure to the underlying drug asset while capturing the full value of its investment in a single liquidity event.